Mineralys Therapeutics, Inc. (MLYS)
Health Care ยท Pharmaceutical Preparations
Mineralys Therapeutics, Inc. (MLYS) is listed on Nasdaq, where its shares have traded since February 10, 2023. SentiSense covers Mineralys Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Jon Congleton is its chief executive officer. The company reports 76 employees, and its corporate website is mineralystx.com.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Latest reported results
Mineralys Therapeutics, Inc. reported revenue of $0.00 for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 220 institutions reported holding MLYS, with 99.6 million shares worth $2.7 billion in aggregate. The largest reported holders were Catalys Pacific, RA Capital Management and BlackRock. Of the 5 largest reported holders, 1 added shares, 1 reduced its position and 3 held their positions unchanged during the quarter.
More on MLYS
- MLYS sentiment: whether news and social coverage of Mineralys Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- MLYS ownership: all 220 reporting institutions, plus insider and congressional trades.
- MLYS financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Mineralys Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Mineralys Therapeutics, Inc. do?
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone.
What sector is MLYS in?
SentiSense classifies Mineralys Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does MLYS stock trade?
Mineralys Therapeutics, Inc. (MLYS) is listed on Nasdaq, where its shares have traded since February 10, 2023.
Who is the CEO of Mineralys Therapeutics, Inc.?
Jon Congleton is the chief executive officer of Mineralys Therapeutics, Inc..